21 (34.4%) patients were found to be surgically inoperable either due to metastasis or local unresectability after laparotomy. If CECT was considered as a sole diagnostic modality, 27 (40.3%) patients would have been surgically inoperable. Among those patients who were deemed operable by PET-CT, DL detected inoperability in 9 patients (14.7%) (peritoneal 8, omental 6, and liver 3). Laparotomy was performed in the DL-wise operable patients (N¼52) and 12 (23.08%) patients were found to be inoperable due to local invasion. Hence the FNR of CECT, PET-CT, and DL in detecting the inoperability was 40.3%,34.4%, and 23.1%, respectively. Out of the 27 patients who were surgically inoperable, DL detected inoperability and futile laparotomies were avoided in 9 patients. The actual rate would have further increased to 15/ 27(55.5%) if the PET-CT detected metastasis (6 patients) were subjected to DL. On univariate analysis, size of the GB mass in CECT significantly correlated with PET-CT detected inoperability (p value ¼ 0.006; Odds ratio 1.64; CI 1.09 to 2.47). The sensitivity, specificity, PPV and NPV of CECT and PET-CT in detecting the lymph node involvement in operable GBC patients were 14.3%, 82.2%, 11.1%, 86% and 57.1%, 79.1%, 30.8%, 86.1%, respectively. Conclusion:Diagnostic laparoscopy obviated futile laparotomies by more than half (55.5%) of unresectable patients and 22.38% in overall patients. Hence DL should be performed in all the operable GBC patients before surgery. PET-CT can be selectively done in patients with larger GB masses in CECT (>1cm). Though PET-CT is more sensitive compared to CECT, both are not an accurate modality in detecting the lymph node involvement in the case of GBC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.